Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1975 6
1976 11
1977 10
1978 4
1979 7
1980 10
1981 11
1982 8
1983 6
1984 8
1985 4
1986 10
1987 4
1988 9
1989 5
1990 15
1991 15
1992 1
1993 6
1994 3
1995 6
1996 2
1998 4
1999 5
2000 5
2001 2
2002 6
2003 18
2004 22
2005 21
2006 27
2007 32
2008 30
2009 34
2010 52
2011 68
2012 84
2013 86
2014 78
2015 106
2016 127
2017 175
2018 225
2019 353
2020 504
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

1,993 results
Results by year
Filters applied: . Clear all
Page 1
Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.
Crippa JA, Guimarães FS, Campos AC, Zuardi AW. Crippa JA, et al. Front Immunol. 2018 Sep 21;9:2009. doi: 10.3389/fimmu.2018.02009. eCollection 2018. Front Immunol. 2018. PMID: 30298064 Free PMC article. Review.
Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the typical subjective effects of marijuana. Objectives: The aim of the present review is to describe the main advances in the development of the exp …
Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the typic …
Clinicians' Guide to Cannabidiol and Hemp Oils.
VanDolah HJ, Bauer BA, Mauck KF. VanDolah HJ, et al. Mayo Clin Proc. 2019 Sep;94(9):1840-1851. doi: 10.1016/j.mayocp.2019.01.003. Epub 2019 Aug 22. Mayo Clin Proc. 2019. PMID: 31447137 Free article. Review.
Cannabidiol (CBD) oils are low tetrahydrocannabinol products derived from Cannabis sativa that have become very popular over the past few years. ...This review is based on a PubMed search using the terms CBD, cannabidiol, hemp oil, and medical marijuan
Cannabidiol (CBD) oils are low tetrahydrocannabinol products derived from Cannabis sativa that have become very popular over t
Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
Burstein S. Burstein S. Bioorg Med Chem. 2015 Apr 1;23(7):1377-85. doi: 10.1016/j.bmc.2015.01.059. Epub 2015 Feb 7. Bioorg Med Chem. 2015. PMID: 25703248 Review.
This was no doubt due to the belief that activity meant psychoactivity that was shown by THC and not by CBD. In retrospect this must be seen as unfortunate since a number of actions of CBD with potential therapeutic benefit were downplayed for many years. ...Topics …
This was no doubt due to the belief that activity meant psychoactivity that was shown by THC and not by CBD. In retrospect this must …
A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential.
White CM. White CM. J Clin Pharmacol. 2019 Jul;59(7):923-934. doi: 10.1002/jcph.1387. Epub 2019 Feb 7. J Clin Pharmacol. 2019. PMID: 30730563 Review.
Cannabidiol (CBD) is a highly touted product for many different disorders among the lay press. ...The control of refractory seizures is a clear exception, with strong evidence of CBD's benefit. Acute CBD dosing before anxiety-provoking events like publ
Cannabidiol (CBD) is a highly touted product for many different disorders among the lay press. ...The control of refractory se
Cannabidiol (CBD) use in psychiatric disorders: A systematic review.
Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F. Bonaccorso S, et al. Neurotoxicology. 2019 Sep;74:282-298. doi: 10.1016/j.neuro.2019.08.002. Epub 2019 Aug 11. Neurotoxicology. 2019. PMID: 31412258 Review.
Cannabidiol (CBD) and delta9-tetrahydrocannabinol (THC) are the most represented phytocannabinoids in Cannabis sativa plants. However, CBD may present with a different activity compared with the psychotomimetic THC. ...
Cannabidiol (CBD) and delta9-tetrahydrocannabinol (THC) are the most represented phytocannabinoids in Cannabis sativa plants.
Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.
McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, Taylor A, Wright S. McGuire P, et al. Am J Psychiatry. 2018 Mar 1;175(3):225-231. doi: 10.1176/appi.ajp.2017.17030325. Epub 2017 Dec 15. Am J Psychiatry. 2018. PMID: 29241357 Clinical Trial.
OBJECTIVE: Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia. ...CBD was well tolerated, and rates of adverse event …
OBJECTIVE: Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors asse …
Cannabidiol, neuroprotection and neuropsychiatric disorders.
Campos AC, Fogaça MV, Sonego AB, Guimarães FS. Campos AC, et al. Pharmacol Res. 2016 Oct;112:119-127. doi: 10.1016/j.phrs.2016.01.033. Epub 2016 Feb 1. Pharmacol Res. 2016. PMID: 26845349 Review.
Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid derived from Cannabis sativa. It has possible therapeutic effects over a broad range of neuropsychiatric disorders. CBD attenuates brain damage associated with neurodegenerative and/or ischemic condi
Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid derived from Cannabis sativa. It has possible therapeutic effects
Cannabidiol Adverse Effects and Toxicity.
Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò FP. Huestis MA, et al. Curr Neuropharmacol. 2019;17(10):974-989. doi: 10.2174/1570159X17666190603171901. Curr Neuropharmacol. 2019. PMID: 31161980 Free PMC article. Review.
BACKGROUND: Currently, there is a great interest in the potential medical use of cannabidiol (CBD), a non-intoxicating cannabinoid. Productive pharmacological research on CBD occurred in the 1970s and intensified recently with many discoveries about the endoc …
BACKGROUND: Currently, there is a great interest in the potential medical use of cannabidiol (CBD), a non-intoxicating cannabi …
Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers.
Martin-Santos R, Crippa JA, Batalla A, Bhattacharyya S, Atakan Z, Borgwardt S, Allen P, Seal M, Langohr K, Farré M, Zuardi AW, McGuire PK. Martin-Santos R, et al. Curr Pharm Des. 2012;18(32):4966-79. doi: 10.2174/138161212802884780. Curr Pharm Des. 2012. PMID: 22716148 Review.
RATIONALE: Animal and humans studies suggest that the two main constituents of cannabis sativa, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have quite different acute effects. However, to date the two compounds have largely been studied separately. ...T …
RATIONALE: Animal and humans studies suggest that the two main constituents of cannabis sativa, delta-9-tetrahydrocannabinol (THC) and ca
Cannabidiol as a Potential Treatment for Anxiety Disorders.
Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Blessing EM, et al. Neurotherapeutics. 2015 Oct;12(4):825-36. doi: 10.1007/s13311-015-0387-1. Neurotherapeutics. 2015. PMID: 26341731 Free PMC article. Review.
Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years has drawn increasing interest as a treatment for a range of neuropsychiatric disorders. ...We found that existing preclinical evidence strongly supports
Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years has drawn in
1,993 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback